Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus GLYCORT.
DETROL vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category C
Category C
Anticholinergic
Anticholinergic